Noradrenaline is the currently recommended first-line vasopressor agent for patients with refractory septic shock. Although vasopressin adjunct therapy might be beneficial, new data from the VANISH trial do not support use of vasopressin as a first-line agent in these patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases
BMC Infectious Diseases Open Access 03 April 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dellinger, R. P. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit. Care Med. 41, 580–637 (2013).
Lauzier, F., Lévy, B., Lamarre, P. & Lesur, O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med. 32, 1782–1789 (2006).
Gordon, A. C. et al. Effect of early vasopressin versus norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316, 509–518 (2016).
Patel, B. M., Chittock, D. R., Russell, J. A. & Walley, K. R. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96, 576–582 (2002).
Russell, J. A. et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N. Engl. J. Med. 358, 877–887 (2008).
Gordon, A. C. et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 36, 83–91 (2010).
Russell, J. A. et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit. Care Med. 37, 811–818 (2009).
Torgersen, C. et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. Intensive Care Med. 37, 1432–1437 (2011).
Gordon, A. C. et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit. Care Med. 42, 1325–1333 (2014).
Wong, H. R. et al. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit. Care Med. 44, e1000–e1003 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Key studies of the effects of vasopressin administration in septic shock (PDF 138 kb)
Rights and permissions
About this article
Cite this article
Vincent, JL., Post, E. Vasopressin: a first-line agent for septic shock?. Nat Rev Nephrol 12, 718–719 (2016). https://doi.org/10.1038/nrneph.2016.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.144
This article is cited by
-
Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases
BMC Infectious Diseases (2023)
-
Current practice and evolving concepts in septic shock resuscitation
Intensive Care Medicine (2022)
